KML-29 is monoacylglycerol lipase inhibitor and an O-hexafluoroisopropyl carbamate analogue of JZL 184.

ABX-1431 is a highly potent, selective, covalent, irreversible, and orally bioavailable, CNS-penetrant MGLL (serine hydrolase monoacylglycerol lipase) inhibitor that has potential use in the treatment of neurological disorders.

WWL-123 is a novel, potent and selective ABHD6 inhibitor with antiepileptic effects. It inhibits ABHD6 with an IC50 of 430 nM.

WWL-70 is a novel, potent inhibitor of α/β-hydrolase domain 6 (ABHD6) with IC50 of 70 nM.

JZL 184 is the first potent, irreversible and selective inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 8 NM.